Dermatology practices automate prior authorization for biologic prescriptions by using software that pulls step-therapy history, prior treatment failures, and severity documentation straight from the EHR, builds the payer- and drug-specific request, and submits and tracks it through approval — while staff still handle the appeals and peer-to-peer calls that need a person. Prior authorization automation for dermatology practices exists because a Dupixent or Skyrizi PA can eat 30+ minutes of staff time and take weeks to resolve, and that shift changes the math on nurse hours, denial rates, and how long a patient waits to start treatment.
Why Biologic Prior Authorization Is the Hardest PA a Derm Practice Handles
Ask any dermatology practice manager which prior authorizations eat the most staff time, and the answer is almost never a topical steroid or a punch biopsy. It's biologics — Dupixent, Skyrizi, Cosentyx, Rinvoq, Tremfya — the drugs that treat psoriasis, atopic dermatitis, and hidradenitis suppurativa when everything cheaper has already failed.
A 2020 JAMA Dermatology study of 11 clinic sites in one department found that biologic PAs cost a median of $15.80 each to process, some took as long as 31 business days to resolve, and the department spent 169.7 staff-hours on prior authorization in a single month (JAMA Dermatology, 2020). That's one department. Multiply it across every clinic prescribing biologics and the math gets ugly fast.
Why is biologic PA harder than everything else on the fee schedule? Two reasons. First, payers require step therapy — documented proof that a patient tried and failed cheaper options (topicals, phototherapy, sometimes methotrexate) before they'll approve a $3,000-a-month injectable. Second, the severity documentation payers want — body surface area, PASI or EASI scores, specific symptom duration — usually lives in scattered chart notes, not a single structured field. Someone has to go find it, every time, for every drug, because every payer's criteria are worded slightly differently.
What happens when a practice can't keep up? Patients wait. The American Medical Association's 2024 survey of 1,000 physicians found 93% believe prior authorization delays access to necessary care, and 78% said PA often or sometimes leads patients to abandon a recommended treatment altogether (AMA, 2024). For a psoriasis patient with cracking, bleeding plaques, a three-week wait for a step-therapy appeal isn't an administrative footnote — it's three more weeks of symptoms. This is the gap prior authorization automation for dermatology practices is meant to close.
The Step-by-Step Workflow for Automated Biologic Prior Authorization
Automating biologic PA doesn't mean replacing the prescriber's judgment. It means removing the manual chart-digging and form-filling that sits between "the dermatologist ordered Skyrizi" and "the payer has everything it needs to say yes." In practice, prior authorization automation for dermatology practices breaks down into seven steps:
- Capture the order. The moment a biologic is prescribed in the EHR, the automation picks up the order — drug, diagnosis code, patient, and payer — without a staff member manually opening a new PA case.
- Pull the step-therapy and failure history. The software scans the chart for prior treatments tried (topical steroids, phototherapy sessions, prior biologics), the dates, and documented outcomes — the exact history most payers require before approving a biologic.
- Pull severity documentation. It locates body surface area, PASI/EASI scores, or the equivalent measure for the diagnosis, plus visit notes describing symptom severity and duration.
- Build the payer- and drug-specific packet. Every payer has its own PA form and its own biologic-specific criteria (a Cigna Dupixent request looks nothing like a UnitedHealthcare Skyrizi request). The system maps the chart data to the exact fields and attachments that payer's rules ask for.
- Submit through the right channel. Portal, fax, or electronic PA (the X12 278 transaction) — whichever the payer accepts — with no re-keying.
- Track status and flag stalls. The request is monitored against the payer's turnaround clock, with alerts when a decision is overdue or additional information is requested.
- Route denials to staff for appeal. When a payer denies or asks for a peer-to-peer, the case gets handed to a staff member with the denial reason and supporting documentation already assembled — not a blank slate.
This is the workflow Honey Health's Prior Authorization agent runs for biologic-heavy dermatology practices: it does the chart-mining and packet-building, submits and tracks the request, and hands off to staff exactly at the point where a human decision — an appeal strategy, a peer-to-peer call — actually matters. Honey Health built the agent around that division of labor because most of the hours in a biologic PA aren't decisions, they're data entry.
What Payers Actually Require for Biologic Approvals
Every biologic PA request is really answering the same three questions, even when the form looks different: What did you try first? Did it fail, and how do you know? How severe is this, right now?
Step therapy documentation is the biggest lift. Most commercial payers want proof of a failed trial of topical therapy and, frequently, phototherapy before approving a systemic biologic for psoriasis — and phototherapy failure is the single most commonly cited requirement in psoriasis biologic denials (step therapy impact study, 2024). For atopic dermatitis, payers typically want documented failure of topical corticosteroids or calcineurin inhibitors. For hidradenitis suppurativa, they'll ask for prior antibiotic courses and sometimes surgical history.
Severity documentation is the second requirement, and it has to match the payer's preferred scale. A PASI score of 12 might clear one payer's bar and fall short of another's. Some payers want body surface area percentage instead. A few still want free-text descriptions of flare frequency and functional impact. None of this is standardized across payers, which is exactly why manual PA work takes so long — staff have to know which payer wants which measurement, then go find it in the chart.
The third piece is drug-specific criteria: dosing history if the patient is switching biologics, prior biologic failures and why, and sometimes lab work (TB screening, hepatitis panels) that payers require before starting certain agents. Automation earns its keep here because it applies the right rule set to the right payer-drug combination every time, instead of relying on a staff member to remember that this payer's Cosentyx criteria differ from last month's Tremfya request.
Common Denial Reasons for Derm Biologics — and What Automation Fixes
Biologic PA denial rates for psoriasis climbed from near 0% in 2009 to 19% in 2014 as payers tightened step-therapy and documentation requirements (Insurance Coverage of Biologics for Psoriasis, 5-Year Chart Review). Most of those denials trace back to a small set of avoidable causes.
Missing step-therapy proof is the most common one — the chart shows the patient is on a biologic, but the specific dates and outcomes of the topical or phototherapy trial the payer wants aren't documented in a way the reviewer can find. Incomplete severity scores are next: a PASI score calculated at the wrong visit, or missing altogether. Wrong form or outdated payer criteria is a close third — payers update biologic PA criteria multiple times a year, and a staff member using last quarter's form gets an automatic denial regardless of clinical merit.
How does automation reduce these specifically? By pulling the step-therapy and severity data directly from structured and unstructured chart fields instead of relying on someone's memory of what the payer wants, and by keeping the payer-specific rule set current so the request goes out on the right form the first time. None of that eliminates clinically appropriate denials — a patient who genuinely hasn't tried a required step will still get denied, and should. It eliminates the denials that happen because of a missing date or the wrong template, which is where most of the avoidable volume sits.
Coordinating with Specialty Pharmacy and Tracking Approval Status
Biologic PA doesn't end at "approved." Most derm biologics ship through a specialty pharmacy, not the practice, which means an approval that never gets communicated to the pharmacy just sits there while the patient waits.
An automated workflow closes that gap by pushing the approval — plus the authorization number and effective dates — to the specialty pharmacy as soon as the payer responds, instead of waiting for a staff member to fax it over during a slow afternoon. It also tracks the pharmacy's fill status back into the practice's system, so staff know if a patient hasn't picked up or started therapy without having to call and ask.
Status tracking matters just as much on the payer side. CAQH's 2024 Index found providers spend an average of 24 minutes per prior authorization handled by phone, fax, or email, versus 16 minutes through a payer portal — and that manual provider-side PA costs an average of $10.97 per transaction against $5.79 for an electronic one (CAQH Index, 2024). Automated tracking checks status across whatever channel the payer uses instead of a staff member calling to ask "any update?" — which is most of where that 24 minutes goes.
Managing Denials, Appeals, and Peer-to-Peer Review
Denials are where automation should hand the case to a person, and any practice evaluating prior authorization automation for dermatology practices should ask a vendor exactly where that handoff happens. The software's job is to make sure staff aren't starting from zero: the denial reason, the original documentation, and the payer's appeal deadline should already be attached to the case when a staff member picks it up.
From there, a person decides on strategy — whether to file a standard appeal with additional documentation, request a peer-to-peer review, or in some cases have the dermatologist call the payer's medical director directly. Peer-to-peer calls are inherently a clinician-to-clinician conversation; no software should attempt to have that conversation for the practice.
What automation can do is make the appeal faster to build. If a denial cites missing step-therapy documentation, the system can resurface the exact chart notes that address it so staff aren't re-searching the record they already searched once. Practices that have automated the intake side of biologic PA report handling meaningfully higher volume per staff member and fewer denials tied to documentation gaps — because the packet going out the door the first time is more complete, and appeals get built from data that's already organized rather than a fresh search.
Frequently Asked Questions
How long does prior authorization for a biologic like Dupixent or Skyrizi usually take?
It varies by payer, but manual biologic PAs can take days to several weeks — one dermatology department study found requests taking as long as 31 business days (JAMA Dermatology, 2020). Automated workflows don't change the payer's decision timeline, but they remove the internal delay caused by staff queuing and re-gathering documentation, which is often where the extra days come from.
What documentation do payers require for step therapy on derm biologics?
Most require dated proof of failed topical treatment and, for psoriasis, often phototherapy, plus the clinical outcome of each trial. Atopic dermatitis PAs typically need documented failure of topical steroids or calcineurin inhibitors. The specific combination and required detail varies by payer and by drug.
Can prior authorization automation actually reduce denials, or just speed up submission?
Both, but not the same way. Automation reduces denials tied to missing documentation, outdated forms, or incomplete severity scores — the avoidable category. It won't overturn a denial for a patient who genuinely hasn't completed a required step; that's a clinical decision, not a paperwork one.
Does automating prior authorization replace the need for PA staff in a dermatology practice?
No. It changes what staff spend time on. Instead of manually pulling chart data and re-keying payer forms, staff focus on denials, appeals, peer-to-peer scheduling, and patient communication — the parts of the process that need judgment, not data entry.
How does biologic PA automation interact with specialty pharmacy coordination?
Once a payer approves a biologic, the authorization details need to reach the specialty pharmacy filling the prescription. Automated workflows push that information to the pharmacy as soon as approval comes through and track fill status, instead of relying on a staff member to fax the approval and follow up manually.
Is prior authorization automation for dermatology practices worth it for a solo or small practice?
It scales down as well as up. A solo dermatologist prescribing a handful of biologics a week faces the same per-request documentation burden as a larger group — automation removes hours of chart-searching regardless of practice size, and the staff time saved often matters more in a small practice where one person is covering PA alongside other front-office work.
